ArticleIJU case reports2020
Two cases of oligometastatic castration-resistant prostate cancer detected by diffusion-weighted whole-body imaging with background body signal suppression.
Article in IJU case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Diffusion-weighted Whole-body Imaging with Background Body Signal Suppression Enables Simultaneous Whole-body Assessments of IgG4-related Diseases.Internal medicine (Tokyo, Japan) · 2026Article
- Article
- Good response with nivolumab and cabozantinib combination therapy in patients with metastatic collecting duct carcinoma with high expression of PD-L1, c-MET, and AXL.CEN case reports · 2025Article
- Two cases of oligometastatic castration-resistant prostate cancer detected by diffusion-weighted whole-body imaging with background body signal suppression.IJU case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTreatment for oligometastasis in prostate cancer has changed from systemic therapy to metastatic lesion-targeted therapy. Early detection of metastatic lesions and assessment of the treatment response have become very important. Therefore, we started to perfume assessments with whole-body magnetic resonance imaging, especially diffusion-weighted imaging with background body signal suppression, as a modality to detect metastasis in patients with prostate cancer. CASE PRESENTATION: We encountered two cases of castration-resistant prostate cancer in which oligometastasis was detected by diffusion-weighted imaging with background body signal suppression. Metastasis-directed therapy was initiated for to treat the lesions in each case. The treatment was effective for disease control and symptom relief. Diffusion-weighted imaging with background body signal suppression could detect new lesions at an early phase and delineate changes in lesions immediately after therapy.
conclusionDiffusion-weighted imaging with background body signal suppression enables early decision-making for metastasis-directed therapy compared with conventional imaging modalities. Further, metastasis-directed therapy targeting oligometastatic lesions detected by diffusion-weighted imaging with background body signal suppression may improve patients' overall survival and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.